Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.

Pediatric blood & cancer - 1 Aug 2011

Donnan Jennifer R, Ungar Wendy J, Mathews Maria, Hancock-Howard Rebecca L, Rahman Proton

Abstract excerpt

BACKGROUND: An increased understanding of the genetic basis of disease creates a demand for personalized medicine and more genetic testing for diagnosis and treatment. The objective was to assess the incremental cost-effectiveness per life-month gained of thiopurine methyltransferase (TPMT) genot...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bone Marrow Diseases
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Trees

Share to Drug Dosage Calculations

Share to Mercaptopurine

Share to Methyltransferases

Share to Ontario

Source

Identifiers

PMID: 21344614
DOI: 10.1002/pbc.22936

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21344614-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.PMID 21344614Read ↗

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseSemantic proximity Read ↗

Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.Semantic proximity Read ↗

Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies.Semantic proximity Read ↗

Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.Semantic proximity Read ↗

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.Semantic proximity Read ↗

Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Semantic proximity Read ↗

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.Semantic proximity Read ↗

Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase statusSemantic proximity Read ↗

Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.